London, April 29th, 2022 – NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies is thrilled to announce the well-deserved promotion of Dr. Gitasha Chand to Managing Director and Dr. Levente Meszaros to Director of Technical Operations of NanoMab Technology (UK) Ltd.
Dr. Chand, who most recently held the position of Clinical Research Director, has been committed to NanoMab since it was founded in 2016 and her extensive experience in the development of radiopharmaceuticals and early phase clinical trials will be invaluable to her new role. The appointment as Managing Director is a true testament to her exceptional leadership capabilities and NanoMab’s success in developing outstanding leaders. As Managing Director, NanoMab is confident the company’s future is in very capable hands and that she is the ideal candidate to lead the company forward and achieve its ambitions.
Dr. Meszaros has served as Senior Project Manager since joining NanoMab in 2018, playing a fundamental role in the technical aspects and preclinical evaluation of the development of 99mTc-NM-01 and NM-02. His wealth of technical expertise in radiopharmaceutical development over the past couple of years has been extraordinary and has better positioned NanoMab to succeed in today’s ever evolving biopharmaceutical industry. We are delighted to appoint him as Director of Technical Operations at NanoMab Technology (UK) Ltd. and are confident that he will excel in his new role.
In addition to the internal promotions, Gitasha and Levente have taken up new roles at NanoMab’s licensee company, Radiopharm Theranostics Ltd (ASX: RAD) to ensure a smooth transition in the development of NanoMab’s platform of single domain antibody products. Gitasha has joined RAD as Global Medical Director and Levente as the Global Director of Translational Science. Radiopharm Theranostics Managing Director and CEO Riccardo Canevari welcomed the new appointments. “We are excited to add these highly experienced and specially skilled professionals to the RAD management team and I am confident (Scot), Gitasha and Levente will add enormous value to RAD in their new roles,” he said.
For more information email: firstname.lastname@example.org
NanoMab Technology Limited is a privately held biopharmaceutical company focusing on cancer precision therapies via the development of radiopharmaceuticals. Our goal is to develop a pipeline of theranostics with our proprietary camelid antibody platform to address the unmet medical need for cancer patients across the world. www.nano-mab.com
Radiopharm Theranostics Ltd (ASX:RAD) is a developer of world-class platform of radiopharmaceutical products for both diagnostics and therapeutic use.